Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.
To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Glucaric acid
Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Toyokuni S | Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis. | 2014 | Redox Rep. | pmid:24257681 |
Onken JE et al. | Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. | 2014 | Nephrol. Dial. Transplant. | pmid:23963731 |
Shah RB et al. | Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose. | 2014 | Int J Pharm | pmid:24440404 |
Tiwari P and Gupta KP | Modulation of miR-203 and its regulators as a function of time during the development of 7, 12 dimethylbenz [a] anthracene induced mouse skin tumors in presence or absence of the antitumor agents. | 2014 | Toxicol. Appl. Pharmacol. | pmid:24792773 |
Elford P et al. | Biodistribution and predictive hepatic gene expression of intravenous iron sucrose. | 2013 Nov-Dec | J Pharmacol Toxicol Methods | pmid:23624021 |
Soufras GD et al. | Fatal anaphylactic reaction to iron sucrose in pregnancy: iron-induced Kounis syndrome? | 2013 Nov-Dec | Indian J Pharmacol | pmid:24347784 |
Mishra A et al. | Fatal anaphylactic reaction to iron sucrose in pregnancy. | 2013 Jan-Feb | Indian J Pharmacol | pmid:23543624 |
Palmer K et al. | Review of available intravenous iron preparations in hemodialysis. | 2013 Apr-Jun | CANNT J | pmid:24069699 |
Potthoff SA and Münch HG | [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease]. | 2013 | Dtsch. Med. Wochenschr. | pmid:23737117 |
Janus N et al. | Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey. | 2013 | Support Care Cancer | pmid:23715817 |